A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jun 2018 Planned primary completion date changed from 7 Oct 2018 to 31 Dec 2018.
- 02 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2013 Planned end date changed from 1 Oct 2018 to 1 Dec 2019 as reported by ClinicalTrials.gov.